Literature DB >> 18256786

Ex vivo expansion of CD34+ and T and NK cells from umbilical cord blood for leukemic BALB/C nude mouse transplantation.

Yaming Wei1,2, Yinfeng Huang3, Yinze Zhang4, Huayou Zhou4, Qiong Cao4, Qingbao Meng4, Juncai Lan4, Longhua Chen5.   

Abstract

CBSCT with low incidence of GVHD is associated with higher rates of delayed engraftment and relapse compared with other stem cells transplants. The immune-mediated effect of NK and cytotoxic T cells against residual tumor cells was shown to prevent relapse and reinduce remission after bone marrow transplantation. We expanded CD34+ and T and NK cells ex vivo in cord blood with different cytokines combination and transplanted into leukemic BALB/C nude mouse. The results showed significant expansion of MNCs and CD34+ cells. The CD3+ T cells increased in the groups containing cytokines cocktail, especially in the group with IL-7 or IL-2. CD56+ NK cells number increased significantly only in a medium containing IL-2. Of the 20 engrafted BALB/C nude mice, 14 survived after 6 weeks transplantation, and the numbers in each group were from 3 to 4. Human CD3+ cells in the bone marrow of the survived mice were analyzed by flow cytometry and showed existing evidences. RT-PCR was used to detect leukemic fusion bcr/abl gene; all mice that experienced expanded cord blood transplantation could not be found to have expression of fusion bcr/abl gene. These suggest that T, NK cells as well as CD34+ cells could be expanded from CB MNCs in the same medium with the combination of cytokines. The expanded CB MNCs could reconstitute hematopoiesis and eliminate minimal residue leukemia disease in transplanted mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256786     DOI: 10.1007/s12185-008-0028-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Evaluation of ex vivo expansion and engraftment in NOD-SCID mice of umbilical cord blood CD34+ cells using the DIDECO "Pluricell System".

Authors:  G Astori; V Adami; G Mambrini; L Bigi; M Cilli; A Facchini; E Falasca; W Malangone; I Panzani; A Degrassi
Journal:  Bone Marrow Transplant       Date:  2005-06       Impact factor: 5.483

Review 2.  Ex vivo expansion of hematopoietic progenitor cells for clinical use.

Authors:  S Scheding; K Kratz-Albers; B Meister; W Brugger; L Kanz
Journal:  Semin Hematol       Date:  1998-07       Impact factor: 3.851

3.  Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.

Authors:  G D'Arena; P Musto; N Cascavilla; G Di Giorgio; S Fusilli; F Zendoli; M Carotenuto
Journal:  Haematologica       Date:  1998-03       Impact factor: 9.941

4.  Large ex vivo expansion of human umbilical cord blood CD4+ and CD8+ T cells.

Authors:  D Skea; N H Chang; R Hedge; B Dabek; T Wong; B Wettlaufer; D Bell
Journal:  J Hematother       Date:  1999-04

5.  Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice.

Authors:  K Ballen; P S Becker; D Greiner; H Valinski; D Shearin; V Berrios; G Dooner; C C Hsieh; J Wuu; L Shultz; J Cerny; J Leif; F M Stewart; P Quesenberry
Journal:  Br J Haematol       Date:  2000-03       Impact factor: 6.998

6.  Functional evaluation of ex vivo expanded cord blood lymphocytes: possible use for adoptive cellular immunotherapy.

Authors:  Hiroshi Azuma; Yoshiko Yamada; Nobuko Shibuya-Fujiwara; Miki Yamaguchi; Hideaki Murahashi; Mitsuhiro Fujihara; Norihiro Sato; Keiko Fukazawa; Kenji Ikebuchi; Hisami Ikeda
Journal:  Exp Hematol       Date:  2002-04       Impact factor: 3.084

Review 7.  Immune reconstitution following hematopoietic stem-cell transplantation.

Authors:  N Novitzky; G M Davison
Journal:  Cytotherapy       Date:  2001       Impact factor: 5.414

8.  Transplantation of ex vivo expanded cord blood.

Authors:  Elizabeth J Shpall; Ralph Quinones; Roger Giller; Chan Zeng; Anna E Baron; Roy B Jones; Scott I Bearman; Yago Nieto; Brian Freed; Nancy Madinger; Christopher J Hogan; Vicki Slat-Vasquez; Peggy Russell; Betsy Blunk; Deborah Schissel; Elaine Hild; Janet Malcolm; William Ward; Ian K McNiece
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

9.  Induction of antitumor cytotoxic activity using CD34+ cord blood cell-derived and irradiated tumor cell-primed dendritic cells.

Authors:  S Fujii; K Fujimoto; M Osato; K Matsui; K Takatsuki; M Kawakita
Journal:  Int J Hematol       Date:  1998-08       Impact factor: 2.490

10.  Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems.

Authors:  M Becker; A Nitsche; C Neumann; J Aumann; I Junghahn; I Fichtner
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.